Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S124000
Reexamination Certificate
active
07902220
ABSTRACT:
The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I):wherein R2, R7, and m are defined in the specification, or a pharmaceutically -acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 6313312 (2001-11-01), Banks et al.
patent: 6469030 (2002-10-01), Farrar et al.
patent: 6479516 (2002-11-01), Gibson et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6610711 (2003-08-01), Armer et al.
patent: 6992090 (2006-01-01), Le Bourdonnec et al.
patent: 7049335 (2006-05-01), McHardy et al.
patent: 7087749 (2006-08-01), Dolle et al.
patent: 2002/0025948 (2002-02-01), Banks et al.
patent: 2004/0186135 (2004-09-01), Dolle et al.
patent: 2004/0204453 (2004-10-01), McHardy et al.
patent: 2004/0254190 (2004-12-01), Liras
patent: 2007/0105863 (2007-05-01), Dolle et al.
patent: 2007/0219278 (2007-09-01), Long et al.
patent: 2008/0207676 (2008-08-01), Dalziel et al.
patent: 2009/0023934 (2009-01-01), Colson et al.
patent: 2009/0062332 (2009-03-01), Saito et al.
patent: 2009/0062334 (2009-03-01), Long et al.
patent: 2009/0062335 (2009-03-01), Long et al.
patent: 2004089908 (2004-10-01), None
patent: WO 2004/089908 (2004-10-01), None
patent: WO 2004/089909 (2004-10-01), None
patent: WO 2007/103187 (2007-09-01), None
Le Bourdonnec et al., “trans-3,4-Dimethyl-4-(3-carboxamidophenyl)piperidines: A Novel Class of μ-Selective Opioid Antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 13 pp. 4459-4462 (2003).
Le Bourdonnec et al., “Elucidation of the Bioactive Conformation of theN-Substitutedtrans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Class of μ-Opioid Receptor Antagonists”, Journal of Medicinal Chemistry, vol. 49, pp. 7278-7289 (2006).
Le Bourdonnec et al., “Synthesis and Pharmacological Evaluation of Novel Octahydro-1H-pyrido[1,2-a]pyrazine as μ-Opioid Receptor Antagonists”, Journal of Medicinal Chemistry, vol. 49, pp. 7290-7306 (2006).
Diaz et al., “SAR and Biological Evaluation of Noveltrans-3,4-dimethyl-4-arylpiperidine Derivatives as Opioid Antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 15 pp. 3844-3848 (2005).
Lu et al., “Substituted Bridged Phenyl Piperidines: Orally Active Growth Hormone Secretagogues”, Bioorganic & Medicinal Chemistry Letters, 13, pp. 1817-1820 (2003).
International Search Report for PCT/US2008/010100.
Church Timothy J.
Frieman Bryan
Jiang Lan
Long Daniel D.
Saito Daisuke Roland
Hagenah Jeffrey A.
Rahmani Niloofar
Saxon Roberta P.
Seaman D. Margaret
Theravance, Inc
LandOfFree
8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735033